CLINICAL TRIALS PROFILE FOR AMISULPRIDE

All Clinical Trials for amisulpride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00126009 ↗	SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients	Completed	Sanofi	Phase 2	2004-05-01	The primary objective is: - To compare the efficacy of the association valproate-amisulpride (400 to 800 mg/day) to the association valproate-haloperidol (5 to 15 mg/day) in bipolar I patients suffering from a manic episode according to DSM IV TR (American Psychiatric Association [APA] 2000) and treated for a 3-month period. The secondary objectives are: - To evaluate the clinical and biological safety of the association valproate-amisulpride to the association valproate-haloperidol; - To assess the patient status 3 weeks and 3 months after inclusion; and - To assess patient satisfaction at 3 months.
NCT00204061 ↗	Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis	Completed	Department of Psychiatry University of Bonn	Phase 4	2001-01-01	The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment.
NCT00204061 ↗	Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis	Completed	German Federal Ministry of Education and Research	Phase 4	2001-01-01	The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment.
NCT00204061 ↗	Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis	Completed	German Research Network On Schizophrenia	Phase 4	2001-01-01	The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment.
NCT00204061 ↗	Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis	Completed	Heinrich-Heine University, Duesseldorf	Phase 4	2001-01-01	The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment.
NCT00204061 ↗	Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis	Completed	Ludwig-Maximilians - University of Munich	Phase 4	2001-01-01	The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment.
NCT00204061 ↗	Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis	Completed	Sanofi-Synthelabo	Phase 4	2001-01-01	The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment.

Clinical Trial Conditions for amisulpride

Condition Name

Condition Name for amisulpride
Intervention	Trials
Schizophrenia	36
Schizoaffective Disorder	4
PONV	4
Schizophreniform Disorder	4

Condition MeSH

Condition MeSH for amisulpride
Intervention	Trials
Schizophrenia	37
Psychotic Disorders	11
Postoperative Nausea and Vomiting	6
Disease	6

Clinical Trial Locations for amisulpride

Trials by Country

Trials by Country for amisulpride
Location	Trials
Germany	25
United States	20
Spain	11
United Kingdom	8
China	8

Trials by US State

Trials by US State for amisulpride
Location	Trials
Ohio	4
Florida	4
North Carolina	3
Massachusetts	3
California	2

Clinical Trial Progress for amisulpride

Clinical Trial Phase

Clinical Trial Phase for amisulpride
Clinical Trial Phase	Trials
Phase 4	24
Phase 3	10
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for amisulpride
Clinical Trial Phase	Trials
Completed	41
Recruiting	7
Not yet recruiting	6

Clinical Trial Sponsors for amisulpride

Sponsor Name

Sponsor Name for amisulpride
Sponsor	Trials
Sanofi	8
Acacia Pharma Ltd	8
Shanghai Mental Health Center	5

Sponsor Type

Sponsor Type for amisulpride
Sponsor	Trials
Other	91
Industry	28
NIH	2